HJB and MabSpace merge to form Transcenta
HJB and MabSpace Biosciences have merged to form Transcenta Holding Ltd, a biotherapeutics company. No financial terms were disclosed. BFC Group Ltd served as financial adviser on the transaction. Dr. Xueming Qian, former founder, chairman and CEO of MabSpace, will serve as CEO of Transcenta while Dr. Jonathan Yining Zhao, co-founder and CEO of HJB, will serve as executive chairman. The backers of HJB and MabSpace include Lilly Asia Ventures, Temasek, Sequoia China, ARCH Venture Partners, Teng Yue Partners and Taikang.
2 January 2019•5 mins read
